Publication date: Dec 30, 2024
Post-COVID-19 syndrome refers to a variety of symptoms that affect different organs in the body and can persist 28 days following exposure to COVID-19. Previous studies have shown that COVID-19 affects not only elderly individuals but also young adults. However, the influence of post-COVID-19 syndrome on young adults has not been studied sufficiently. Therefore, the aim of this study was to determine the prevalence and characteristics of post-COVID-19 manifestations in young adults. An analytical cross-sectional online questionnaire was distributed from July 2022 to July 2023 to health sciences students in Saudi Arabia. The study used a non-probability convenience sampling technique, and the sample size was calculated to be 464. The survey included questions about the participants’ demographics, health records, COVID-19 results, duration of infection, and previous and current COVID-19 symptoms. Illness severity and management were evaluated using the COVID Experiences (COVEX) Symptoms and Diagnoses module, and Patient Health Questionnaire (PHQ-9) was used to assess depression. According to the inclusion criteria, 428 participants were divided into three groups: those who fully recovered within 14 days of the acute phase (76. 4%), those with prolonged symptoms that resolved within 28 days (16. 8%), and those with persistent symptoms for more than 28 days (6. 8%). The symptom development frequency during the acute phase significantly differed among the three groups: headache (p = 0. 038), loss of smell and taste (p =
Open Access PDF
| Concepts | Keywords |
|---|---|
| Headache | COVID-19 |
| July | Long COVID |
| Saudi | Persistent symptoms |
| Students | Post-COVID-19 |
| Taste | SARS-Cov-2 |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | COVID-19 |
| disease | MESH | syndrome |
| disease | MESH | infection |
| disease | MESH | depression |
| disease | IDO | symptom |
| disease | MESH | loss of smell |
| pathway | REACTOME | Reproduction |
| disease | MESH | long COVID |
| disease | MESH | lifestyle |
| disease | MESH | joint pain |
| disease | MESH | anxiety |
| disease | MESH | tachycardia |
| disease | MESH | dyspnea |
| disease | MESH | chest pain |
| pathway | REACTOME | Immune System |
| disease | MESH | death |
| disease | MESH | neuralgia |
| disease | MESH | rhinitis |
| disease | MESH | insomnia |
| disease | MESH | mental fog |
| disease | MESH | anorexia |
| disease | MESH | complications |
| drug | DRUGBANK | Ademetionine |
| disease | MESH | pharyngitis |
| disease | MESH | adenopathy |
| disease | MESH | migraine |
| drug | DRUGBANK | Coenzyme M |
| disease | MESH | critical illness |
| disease | IDO | history |
| drug | DRUGBANK | Trihexyphenidyl |
| drug | DRUGBANK | Cysteamine |
| disease | IDO | process |
| drug | DRUGBANK | (S)-Des-Me-Ampa |
| disease | IDO | cell |
| disease | MESH | taste loss |